

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

OTSUKA PHARMACEUTICAL CO., LTD.,)
)
)
Plaintiff,)
)
)
v.) C.A. _____
)
)
TEVA PHARMACEUTICALS INC., TEVA)
PHARMACEUTICALS USA, INC., and)
TEVA PHARMACEUTICAL INDUSTRIES)
LTD.,)
)
)
Defendants.)

**SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN
ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiff Otsuka Pharmaceutical Co., Ltd. (“Otsuka”) hereby provides the information below with respect to the deadlines set forth in 21 U.S.C. § 355(j):

Date Patentee Received Notice:	March 9, 2022
Date of Expiration of the '730 Patent:	September 1, 2026
Date of Expiration of the '694 Patent:	April 7, 2030
Date of Expiration of the '735 Patent:	August 14, 2028
Thirty Month Stay Deadline:	September 9, 2024

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Jeremy A. Tigan

OF COUNSEL:

John D. Murnane
Joshua I. Rothman
Alicia A. Russo
Zachary L. Garrett
VENABLE LLP
1290 Avenue of the Americas
New York, NY 10104-3800
(212) 218-2100

Jack B. Blumenfeld (#1014)
Jeremy A. Tigan (#5239)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
jtigan@morrisnichols.com

*Attorneys for Plaintiff
Otsuka Pharmaceutical Co., Ltd.*

April 22, 2022